Epizyme

2,123

$17.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.86 (-4.67%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Epizyme and other stocks, options, ETFs, and crypto commission-free!

About EPZM

Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company. Read More The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Employees
203
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
1.77B
Price-Earnings Ratio
Dividend Yield
Average Volume
750.32K
High Today
$18.46
Low Today
$16.57
Open Price
$18.35
Volume
1.05M
52 Week High
$27.82
52 Week Low
$9.74

Collections

EPZM News

ReutersMay 26

Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT

Q1 2020 Epizyme Inc Earnings Call Cambridge May 26, 2020 (Thomson StreetEvents) -- Edited Transcript of Epizyme Inc earnings conference call or presentation Mo
15

EPZM Earnings

-$0.74
-$0.49
-$0.25
$0.00
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
per share
Actual
Expected Aug 6, Pre-Market

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.